RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern-Reference-Cited by-同舟云学术

RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern

Published:2022 Issue:13 Volume:58 Page:2120-2123
ISSN:1359-7345
Container-title:Chemical Communications
language:en
Short-container-title:Chem. Commun.

Author:

Zhou Shi-Hao¹,Zhang Ru-Yan¹,Zhang Hai-Wei²,Liu Yan-Ling¹,Wen Yu¹,Wang Jian¹,Li Yu-Ting¹,You Zi-Wei¹,Yin Xu-Guang¹,Qiu Hong³,Gong Rui²,Yang Guang-Fu¹,Guo Jun¹^ORCID

Affiliation:

1. Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, International Joint Research Center for Intelligent Biosensing Technology and Health, Hubei International Scientific and Technological Cooperation Base of Pesticide and Green Synthesis, College of Chemistry, Central China Normal University, Wuhan, 430079, China

2. CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China

3. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Abstract

An RBD-based subunit vaccine with a built-in TLR1/2 agonist induced potent immune responses against SARS-CoV-2 and variants of concern.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Wuhan Municipal Science and Technology Bureau

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,Metals and Alloys,Surfaces, Coatings and Films,General Chemistry,Ceramics and Composites,Electronic, Optical and Magnetic Materials,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CC/D1CC06520C

Reference37 articles.

1. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

2. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

3. Synthetic Homogeneous Glycoforms of the SARS‐CoV‐2 Spike Receptor‐Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies

4. Key Considerations for the Development of Safe and Effective SARS‐CoV‐2 Subunit Vaccine: A Peptide‐Based Vaccine Alternative

5. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy;International Journal of Biological Macromolecules;2024-10

2. Multifunctional Lipidated Protein Carrier with a Built-In Adjuvant as a Universal Vaccine Platform Potently Elevates Immunogenicity of Weak Antigens;Journal of Medicinal Chemistry;2024-04-08

3. Recent advances in chemical protein synthesis: method developments and biological applications;Science China Chemistry;2024-03-12

4. Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2;Chemical Communications;2024

5. Role of toll‐like receptors in the pathogenesis of COVID‐19: Current and future perspectives;Scandinavian Journal of Immunology;2023-05-07